(0.78%) 5 167.72 points
(0.25%) 38 773 points
(0.92%) 16 304 points
(0.52%) $78.52
(2.57%) $2.20
(1.16%) $2 335.30
(3.65%) $27.66
(-0.01%) $965.20
(-0.02%) $0.929
(-0.37%) $10.83
(-0.13%) $0.796
(-0.11%) $91.35
1.00% INR 1 163.20
Live Chart Being Loaded With Signals
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India...
Stats | |
---|---|
Объем за сегодня | 1.28M |
Средний объем | 2.20M |
Рыночная капитализация | 681.56B |
EPS | INR0 ( 2024-02-11 ) |
Дата следующего отчета о доходах | ( INR14.00 ) 2024-05-25 |
Last Dividend | INR3.00 ( 2023-02-17 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 24.63 |
ATR14 | INR0.939 (0.08%) |
Объем Корреляция
Aurobindo Pharma Limited Корреляция
10 Самые положительные корреляции | |
---|---|
SETF10GILT.NS | 0.946 |
IZMO.NS | 0.936 |
ADORWELD.NS | 0.933 |
ANMOL.NS | 0.927 |
GTNTEX.NS | 0.92 |
ANURAS.NS | 0.918 |
FOCUS.NS | 0.918 |
TIIL.NS | 0.917 |
GISOLUTION.NS | 0.914 |
KIRLOSIND.NS | 0.913 |
10 Самые отрицательные корреляции | |
---|---|
STARTECK.NS | -0.883 |
GENESYS.NS | -0.878 |
EASTSILK.NS | -0.871 |
SEYAIND.NS | -0.871 |
ORTINLAB.NS | -0.864 |
DEEPINDS.NS | -0.862 |
GRMOVER.NS | -0.859 |
KOHINOOR.NS | -0.856 |
CLNINDIA.NS | -0.853 |
ESABINDIA.NS | -0.852 |
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Aurobindo Pharma Limited Корреляция - Валюта/Сырье
Aurobindo Pharma Limited Финансовые показатели
Annual | 2022 |
Выручка: | INR246.17B |
Валовая прибыль: | INR133.24B (54.12 %) |
EPS: | INR32.90 |
FY | 2022 |
Выручка: | INR246.17B |
Валовая прибыль: | INR133.24B (54.12 %) |
EPS: | INR32.90 |
FY | 2022 |
Выручка: | INR233.67B |
Валовая прибыль: | INR132.26B (56.60 %) |
EPS: | INR45.19 |
FY | 2021 |
Выручка: | INR245.58B |
Валовая прибыль: | INR146.55B (59.68 %) |
EPS: | INR91.05 |
Financial Reports:
No articles found.
Aurobindo Pharma Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR3.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.150 | 2001-09-12 |
Last Dividend | INR3.00 | 2023-02-17 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 42 | -- |
Total Paid Out | INR38.23 | -- |
Avg. Dividend % Per Year | 0.47% | -- |
Score | 2.7 | -- |
Div. Sustainability Score | 4.12 | |
Div.Growth Potential Score | 3.15 | |
Div. Directional Score | 3.64 | -- |
Year | Amount | Yield |
---|---|---|
2001 | INR0 | 0.00% |
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR2.25 | 0.36% |
2019 | INR2.50 | 0.34% |
2020 | INR4.25 | 0.93% |
2021 | INR4.50 | 0.49% |
2022 | INR6.00 | 0.82% |
2023 | INR3.00 | 0.69% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SYMPHONY.NS | Dividend Knight | 2023-08-04 | Semi-Annually | 14 | 0.47% | |
NESCO.NS | Dividend Junior | 2023-07-28 | Annually | 17 | 0.40% | |
IDBI.NS | Dividend Junior | 2023-07-06 | Sporadic | 27 | 0.48% | |
CERA.NS | Dividend Junior | 2023-06-20 | Annually | 17 | 0.39% | |
RVNL.NS | Dividend Knight | 2023-09-20 | Annually | 6 | 3.08% | |
LSIL.NS | Dividend Junior | 2023-07-17 | Annually | 3 | 0.23% | |
GEOJITFSL.NS | Dividend Knight | 2023-06-30 | Annually | 20 | 2.79% | |
ARVIND.NS | Dividend Junior | 2023-07-21 | Sporadic | 20 | 0.59% | |
THEMISMED.NS | Dividend Junior | 2023-08-31 | Sporadic | 18 | 0.39% | |
ORIENTELEC.NS | Dividend Junior | 2023-07-26 | Semi-Annually | 7 | 0.41% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.100 | 1.500 | 7.99 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.101 | 1.500 | 9.99 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 15.99 | 1.000 | 5.19 | 5.19 | [3 - 30] |
operatingCashFlowPerShareTTM | 51.10 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 25.58 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.548 | 1.000 | 4.20 | 4.20 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.148 | 1.000 | 9.03 | 9.03 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 24.38 | 1.000 | 7.64 | 0 | [1 - 100] |
returnOnEquityTTM | 0.101 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 25.58 | 2.00 | 1.474 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.390 | 1.500 | 0.242 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 51.10 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.421 | 1.500 | -6.14 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.109 | 1.000 | 9.79 | 0 | [0.1 - 0.5] |
Total Score | 3.15 |
Aurobindo Pharma Limited
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа